Deferasirox?

Deferasirox Overview and Patent Status

Deferasirox is an oral iron chelator used in the treatment of patients with transfusional iron overload, primarily those with beta-thalassemia major or sickle cell disease.[1] It works by chelating iron and helping to remove it from the body through the gastrointestinal tract.

Why are companies challenging the patent for Deferasirox?

The patent for Deferasirox was held by Novartis, a Swiss multinational pharmaceutical company, until 2019. However, other companies have challenged the patent, arguing that it is too broad or that the formulation is not novel enough. One of the main challenges came from Teva Pharmaceuticals,[2] which was granted approval for a generic version in 2019. However, this approval is subject to ongoing patent litigation.

How does Deferasirox compare to other iron chelators?

Deferasirox is typically used in combination with other medications or as an alternative to other iron chelators, such as deferoxamine (Desferal). It has a higher oral bioavailability compared to deferoxamine, which means it is more effective and easier to take orally. Additionally, Deferasirox has a different efficacy profile compared to deferiprone,[3] which may make it more suitable for specific patient populations.

What side effects are patients asking about?

Common side effects of Deferasirox include gastrointestinal issues, such as nausea, vomiting, and diarrhea. Less common side effects can include skin rash, elevated liver enzymes, and reduced kidney function. Patients should discuss their medical history and potential side effects with their healthcare provider before starting treatment.

When does the patent expire?

The patent for Deferasirox expired in the US in 2019, with the exclusivity period expiring in 2024.[4] This means that other companies can manufacture and market generic versions of Deferasirox after this date.

Sources:

[1] https://www.drugs.com/pro/deferasirox.html
[2] https://www.tevapharm.com/our-products/generic-drugs/deferisirox/
[3] https://www.nhs.uk/conditions/iron-chelation/
[4] https://www.drugpatentwatch.com/drug/deferisirox